These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 36796935)
1. Parental acceptance of and preferences for administration of routine varicella vaccination in the UK: A study to inform policy. Sherman SM; Lingley-Heath N; Lai J; Sim J; Bedford H Vaccine; 2023 Feb; 41(8):1438-1446. PubMed ID: 36796935 [TBL] [Abstract][Full Text] [Related]
2. UK healthcare professionals' attitudes towards the introduction of varicella vaccine into the routine childhood vaccination schedule and their preferences for administration. Sherman SM; Allerton-Price C; Lingley-Heath N; Lai J; Bedford H Vaccine; 2024 Apr; 42(10):2621-2627. PubMed ID: 38480101 [TBL] [Abstract][Full Text] [Related]
3. Combined measles-mumps-rubella-varicella vaccine and febrile convulsions: the risk considered in the broad context. Casabona G; Berton O; Singh T; Knuf M; Bonanni P Expert Rev Vaccines; 2023; 22(1):764-776. PubMed ID: 37642012 [TBL] [Abstract][Full Text] [Related]
4. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). Marin M; Broder KR; Temte JL; Snider DE; Seward JF; MMWR Recomm Rep; 2010 May; 59(RR-3):1-12. PubMed ID: 20448530 [TBL] [Abstract][Full Text] [Related]
5. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine. Nolan T; McIntyre P; Roberton D; Descamps D Vaccine; 2002 Dec; 21(3-4):281-9. PubMed ID: 12450703 [TBL] [Abstract][Full Text] [Related]
6. Vaccines for measles, mumps, rubella, and varicella in children. Di Pietrantonj C; Rivetti A; Marchione P; Debalini MG; Demicheli V Cochrane Database Syst Rev; 2020 Apr; 4(4):CD004407. PubMed ID: 32309885 [TBL] [Abstract][Full Text] [Related]
7. Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial. Prymula R; Bergsaker MR; Esposito S; Gothefors L; Man S; Snegova N; Štefkovičova M; Usonis V; Wysocki J; Douha M; Vassilev V; Nicholson O; Innis BL; Willems P Lancet; 2014 Apr; 383(9925):1313-1324. PubMed ID: 24485548 [TBL] [Abstract][Full Text] [Related]
8. Vaccines for measles, mumps, rubella, and varicella in children. Di Pietrantonj C; Rivetti A; Marchione P; Debalini MG; Demicheli V Cochrane Database Syst Rev; 2021 Nov; 11(11):CD004407. PubMed ID: 34806766 [TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of early vaccination with two doses of a combined measles-mumps-rubella-varicella vaccine in healthy Indian children from 9 months of age: a phase III, randomised, non-inferiority trial. Lalwani S; Chatterjee S; Balasubramanian S; Bavdekar A; Mehta S; Datta S; Povey M; Henry O BMJ Open; 2015 Sep; 5(9):e007202. PubMed ID: 26362659 [TBL] [Abstract][Full Text] [Related]
10. Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: 10-year follow-up of a phase 3 multicentre, observer-blind, randomised, controlled trial. Povey M; Henry O; Riise Bergsaker MA; Chlibek R; Esposito S; Flodmark CE; Gothefors L; Man S; Silfverdal SA; Štefkovičová M; Usonis V; Wysocki J; Gillard P; Prymula R Lancet Infect Dis; 2019 Mar; 19(3):287-297. PubMed ID: 30765242 [TBL] [Abstract][Full Text] [Related]
11. Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children. Knuf M; Zepp F; Helm K; Maurer H; Prieler A; Kieninger-Baum D; Douha M; Willems P Eur J Pediatr; 2012 Mar; 171(3):463-70. PubMed ID: 21935584 [TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and reactogenicity of tetravalent vaccine for measles, mumps, rubella and varicella (MMRV) in healthy children: a meta-analysis of randomized controlled trials. Leung JH; Hirai HW; Tsoi KK Expert Rev Vaccines; 2015; 14(8):1149-57. PubMed ID: 26081133 [TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life. Schuster V; Otto W; Maurer L; Tcherepnine P; Pfletschinger U; Kindler K; Soemantri P; Walther U; Macholdt U; Douha M; Pierson P; Willems P Pediatr Infect Dis J; 2008 Aug; 27(8):724-30. PubMed ID: 18600190 [TBL] [Abstract][Full Text] [Related]
15. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody. Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ; Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432 [TBL] [Abstract][Full Text] [Related]
16. A combination vaccine against measles, mumps, rubella and varicella. Knuf M; Faber J; Barth I; Habermehl P Drugs Today (Barc); 2008 Apr; 44(4):279-92. PubMed ID: 18536786 [TBL] [Abstract][Full Text] [Related]
17. Parental perceptions of chickenpox and the varicella vaccine: A qualitative systematic review. Jordan Z; Rowland E Vaccine; 2024 Jan; 42(2):75-83. PubMed ID: 38129287 [TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children. Knuf M; Habermehl P; Zepp F; Mannhardt W; Kuttnig M; Muttonen P; Prieler A; Maurer H; Bisanz H; Tornieporth N; Descamps D; Willems P Pediatr Infect Dis J; 2006 Jan; 25(1):12-8. PubMed ID: 16395096 [TBL] [Abstract][Full Text] [Related]
19. [Chickenpox: sufficient reasons for the introduction of vaccination]. Rümke H; de Groot R Ned Tijdschr Geneeskd; 2006 Dec; 150(48):2630-2. PubMed ID: 17205937 [TBL] [Abstract][Full Text] [Related]
20. One or two doses of live varicella virus-containing vaccines: Efficacy, persistence of immune responses, and safety six years after administration in healthy children during their second year of life. Henry O; Brzostek J; Czajka H; Leviniene G; Reshetko O; Gasparini R; Pazdiora P; Plesca D; Desole MG; Kevalas R; Gabutti G; Povey M; Innis B Vaccine; 2018 Jan; 36(3):381-387. PubMed ID: 29224964 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]